LONDON (ShareCast) - (Sharecast News) - Merck said on Wednesday that it has signed an exclusive global licensee agreement with Chinese biopharmaceutical firm Hansoh Pharma for weight-loss drug HS-10535.
The drug is an investigational preclinical oral small molecule GLP-1 receptor agonist.

Under the agreement, Hansoh has granted Merck an exclusive global license to develop, manufacture and commercialise HS-10535. Hansoh will receive an upfront payment of $112m and is eligible to receive up to $1.9bn in milestone payments associated with the development, regulatory approval and commercialisation of the candidate, as well as royalties on sales.

Hansoh Pharma may co-promote or solely commercialise HS-10535 in China subject to certain conditions.

Merck said it will record a pre-tax charge of $112m, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.

Dr. Dean Y. Li, president, Merck Research Laboratorie, said: "We continue to leverage science-driven business development to augment and complement our robust pipeline.

"Through this agreement, we aim to build on our experience targeting incretin biology to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE